• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

NeuroRX, TFF Pharmaceuticals enter feasibility agreement for Zyesami dry powder for COVID-19

March 10, 2021 By Sean Whooley

NeuroRx TFF PharmaceuticalsNeuroRx TFF PharmaceuticalsNeuroRx and TFF Pharmaceuticals (NSDQ:TFFP) announced a feasibility agreement for the former’s Zyesami therapeutic.

Zyesami (aviptadil, synthetic VIP) materials are set to be delivered to TFF to perform feasibility formulation work and testing in an effort to identify an optimal, long-term, stable formulation of Zyesami into a dry powder form for aerosol delivery directly to the lungs, according to a news release.

The therapeutic is a synthetic form of a naturally occurring peptide — vasoactive intestinal peptide (VIP) — found in the lung and known to protect the Alveolar Type II cell targeted by SARS-CoV-2, the virus causing COVID-19. The decreased surfactant production and increased cytokine production caused by COVID-19 can also be a common pathway for sepsis-induced acute respiratory distress syndrome (ARDS) and checkpoint inhibitor pneumonitis associated with certain cancer drugs.

NeuroRx and TFF Pharmaceuticals believe the ability to deliver VIP directly to the lung via inhalation through the dry powder formulation of Zyesami could have important therapeutic implications and potentially expand the application of the drug to patients who are less severely affected by COVID-19.

“We are excited that Zyesami has demonstrated a highly significant reduction in time to hospital discharge for seriously ill COVID-19 patients treated with High Flow Nasal Oxygen, along with an increased likelihood of recovery and excellent safety,” NeuroRx CEO Dr. Jonathan C. Javitt said in the release. “Although our current production methods yield a drug that is sufficiently stable for emergency use, a long-term, shelf-stable formulation will be needed for ongoing use of Zyesami, once the pandemic subsides. The thin-film freezing technology holds great promise in potentially making this available to patients with other stages of COVID-19 with an inhaled form of Zyesami.”

“The work being done by the NeuroRx team with Zyesami on behalf of critically ill patients with COVID-19 respiratory failure is both remarkable and gratifying,” added TFF Pharmaceuticals president & CEO Glenn Mattes. “The potential opportunity to bring this important new therapeutic to patients earlier in the treatment cycle is exciting. We are very pleased to be collaborating with the NeuroRx Team with our thin-film freezing technology.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals, Research & Development Tagged With: coronavirus, COVID-19, NeuroRx, TFF Pharmaceuticals

IN CASE YOU MISSED IT

  • Medtronic to invest $50M in India Diabetes center
  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS